You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思(01167.HK)抗腫瘤藥物與西妥昔單抗注射液聯用試驗獲批
阿思達克 12-06 09:55
加科思(01167.HK)公布,其自主研發的KRAS G12C抑制劑JAB-21822與西妥昔單抗注射液的聯用試驗,於上周五(3日)獲得中國國家藥監局評審中心批准。 公司指出,該項臨床試驗獲批後,公司將在中國開啟一項I/II期、開放標籤、多中心、劑量遞增和擴展的臨床研究,旨在探索JAB-21822聯合西妥昔單抗在KRAS G12C突變的晚期結直腸癌患者中的安全性、耐受性和初步療效。 JAB-21822是公司自主研發的KRAS G12C小分子抗腫瘤藥,是潛在的同類最佳項目,目前已在中國和美國進行臨床試驗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account